title: [Analysis of clinical-biological features of adult acute lymphoblastic leukemia].
abstract: BACKGROUND
  Acute lymphoblastic leukemia (ALL) is a clonal disease characterized by a proliferation of immature cells. In immunophenotypic, cytogenetic and molecular studies, it is a heterogeneous disease with diverse manifestations and prognoses. The treatment is complex and is associated with complications during its course.
  
  
  METHODS
  A prospective study of cohort of patients with ALL. Subjects were recruited consecutively from April 2010 to November 2012 in the Specialties Hospital, /MSS.
  
  
  RESULTS
  We included 29 patients with ALL; of 16 females (55%) and 13 males (45%), 18 (64%) were treated with modified BFM, seven (25%) HiperCVAD, and three (11 %) others. In all, 70% achieved complete remission, and 8.5% partial responses. Induction mortality in five patients (17%). Consolidation mortality in three (13%). Relapse 33%, with a mean of eight months (5- 16 months), overall survival five months. At 26 months of follow-up, 13 patients (45%) maintained RC. Disease-free survival of 10 months and overall survival of 12 months was observed.
  
  
  CONCLUSIONS
  The majority of patients, regardless of risk, reach complete remission. We found that the clinical and biological characteristics showed no significant differences related to the outcome. lmmunochemotherapy treatment may improve response.
authors.affiliation: Servicio de Hematología, Unidad Médica de Alta Especialidad, HE, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Mexico.
authors.forename: Rosbiney
authors.initials: R
authors.lastname: Díaz-Ruiz
authors.affiliation: Servicio de Hematología, Unidad Médica de Alta Especialidad, HE, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Mexico.
authors.forename: Lilia
authors.initials: L
authors.lastname: Aguilar-López
authors.affiliation: Servicio de Hematología, Unidad Médica de Alta Especialidad, HE, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Mexico.
authors.forename: Arturo
authors.initials: A
authors.lastname: Vega-Ruiz
authors.affiliation: Servicio de Hematología, Unidad Médica de Alta Especialidad, HE, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Mexico.
authors.forename: Oscar
authors.initials: O
authors.lastname: Garcés-Ruiz
authors.affiliation: Unidad de Investigación en Epidemiología Clínica, Unidad Médica de Alta Especialidad, HE, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Mexico.|Dirección de Investigación Ciencias de la Salud, Universidad Autónoma de Guadalajara, Guadalajara, Jal., Mexico.
authors.forename: Arnulfo
authors.initials: A
authors.lastname: Nava-Zavala
authors.affiliation: Servicio de Hematología, Unidad Médica de Alta Especialidad, HE, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Mexico.
authors.forename: Benjamín
authors.initials: B
authors.lastname: Rubio-Jurado
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000188:drug therapy; D011446:Prospective Studies; D055815:Young Adult